To overcome these problems, scientists developed a novel class of CAR-T cells engineered to express an enzyme that activated a systemically administered small-molecule prodrug in situ at a tumor site.
[Nature Chemical Biology]
6445212
AAAAAAAA
items
1
apa
0
default
asc
1
170190
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
